Respiratory Disease Vaccine Market Sees Rapid Global Uptake

Respiratory Disease Vaccine Market Size, Dynamics and Key Players with Forecast

The global respiratory disease vaccine market size is calculated at USD 65.72 billion in 2025, grew to USD 68.43 billion in 2026, and is projected to reach around USD 98.41 billion by 2035. The market is expanding at a CAGR of 4.12% between 2026 and 2035.

The respiratory disease vaccine market is primarily driven by the increasing prevalence of respiratory diseases and the growing awareness of disease prevention. Vaccine manufacturing is favored by rapid adoption and pipeline expansion of mRNA and recombinant platforms. Increasing R&D investments and favorable regulatory policies augment the market. Artificial intelligence (AI) assists researchers in designing novel vaccines and determining their efficacy.

Key Takeaways

• The respiratory disease vaccine market will likely exceed USD 65.72 billion by 2025.
• Valuation is projected to hit USD 98.41 billion by 2035.
• Estimated to grow at a CAGR of 4.12% starting from 2026 to 2035.
• North America held a major revenue share of the market in 2024.
• Asia-Pacific is expected to witness the fastest growth during the predicted timeframe.
• By target disease/indication, the influenza vaccines segment dominated the respiratory disease vaccine market with a share of approximately 35-40% in 2024.
• By target disease/indication, the respiratory syncytial virus (RSV) vaccines segment is expected to witness the fastest growth in the market over the forecast period.
• By vaccine technology/platform, the inactivated/split & subunit vaccines segment accounted for the highest revenue share of approximately 40% in the market in 2024.
• By vaccine technology/platform, the mRNA vaccines segment is expected to show the fastest growth over the forecast period.
• By age group/indication population, the pediatrics segment led the market in 2024.
• By age group/indication population, the maternal immunization segment is expected to grow at the fastest CAGR in the market during the forecast period.
• By route/formulation, the intramuscular injection segment held a dominant revenue share of the respiratory disease vaccine market in 2024.
• By route/formulation, the intranasal/mucosal segment is expected to grow with the highest CAGR in the market during the studied years.
• By end-user/distribution channel, the public health programs/government immunization campaigns segment contributed the biggest revenue share of the market in 2024.
• By end-user/distribution channel, the retail pharmacies & occupational/workplace vaccination segment is expected to expand rapidly in the market in the coming years.

Quick Facts Table

Respiratory Disease Vaccine: Immunity for Breathing

The respiratory disease vaccine market is experiencing robust growth, driven by public-health vaccination programs, seasonal immunization campaigns, pandemic preparedness, technological innovations, and demographic aging. It comprises vaccines and vaccine delivery technologies developed to prevent or reduce the severity of infectious respiratory diseases, notably influenza, pneumococcal disease, respiratory syncytial virus (RSV), SARS-CoV-2 (COVID-19), pertussis (whooping cough), and other viral/bacterial respiratory pathogens. Includes vaccine development (platforms and formulations), manufacturing (bulk antigen, adjuvants), distribution & immunization programs, and related services (cold chain, surveillance).

Respiratory Disease Vaccine Market Outlook

• Industry Growth Overview: The market is expected to grow rapidly in emerging markets, driven by the local manufacturing and tiered pricing influencing uptake. Advances in vaccine manufacturing, such as mRNA and recombinant protein, also boost market growth.
• Sustainability Trends: Key players are adopting sustainable practices in vaccine development, manufacturing, packaging, and supply chain. For instance, GSK aims to achieve a 90% reduction in carbon emissions by 2045 and to contribute to a more natural, positive world.
• Major Investors: Numerous government and private organizations provide funding for expanding vaccine manufacturing infrastructure and support the design of novel vaccines. TCGX, Goldman Sachs Alternatives, and Avoro Ventures are some private investors.

Smart Immunity for Respiratory Health

AI plays a vital role in the respiratory disease vaccine market by generating effective vaccines and addressing challenges in conventional vaccine development, such as high cost and time-consuming nature. AI and machine learning (ML) algorithms can help predict and detect the target epitopes that activate the immune system. They can analyze vast amounts of data and predict immunological response to a particular vaccine. Moreover, AI and ML can streamline the manufacturing and supply chain for respiratory disease vaccines, ensuring effective distribution to a larger population.

Segmental Insights

Target Disease/Indication Insights

Which Target Disease/Indication Segment Dominated the Respiratory Disease Vaccine Market?

The influenza vaccines segment held a dominant presence in the market with a share of approximately 36% in 2024, due to the rising incidence of seasonal influenza and the availability of broad target populations, such as children, adults, and the elderly. The U.S. reported 489,579 influenza cases during the 2024-25 influenza season, with peak activity observed during the week ending February 2025. As of 2024, three types of influenza vaccines are available: inactivated, recombinant, and live attenuated vaccines.

Respiratory Syncytial Virus (RSV) Vaccines

The respiratory syncytial virus (RSV) vaccines segment is expected to grow at the fastest CAGR in the respiratory disease vaccine market during the forecast period. RSV vaccines are rapidly expanding commercial opportunities for both maternal and older-age immunization programs. They reduce the risk of severe respiratory illnesses, such as pneumonia and bronchiolitis. They are mostly given to pregnant women and older adults 75 years and above.

Pneumococcal Vaccines (PCV & PPSV)

The pneumococcal vaccines segment is expected to grow notably, driven by rising pneumonia incidence and growing demand for pediatric immunization. UNICEF reported 1,400 pneumonia cases per 100,000 children annually in the world. Pneumococcal vaccines are available in conjugate (PCV) and polysaccharide (PPSV) forms for adults and children. They help protect against pneumococcal infections, including invasive disease.

Vaccine Technology/Platform Insights

Why Did the Inactivated/Split & Subunit Vaccines Segment Dominate the Respiratory Disease Vaccine Market?

The inactivated/split & subunit vaccines segment held the largest revenue share of approximately 40% in the market in 2024, due to lower chances of virulent activity, ease of production, and high stability. Inactivated vaccines are available in three forms such as whole virus, split virus, and subunit virus. They are highly preferred as they reduce infectivity and prevent the infection. Unlike live vaccines, they do not replicate and are not contraindicated for immunocompromised individuals.

mRNA Vaccines

The mRNA vaccines segment is expected to grow with the highest CAGR in the respiratory disease vaccine market during the studied years. The demand for mRNA vaccines is increasing due to advances in genomic technologies and recent FDA approvals. The COVID-19 pandemic has witnessed a surge in mRNA vaccine development, benefiting the global population. In August 2024, the U.S. FDA approved and granted emergency use authorization (EUA) for updated mRNA COVID-19 vaccines.

Recombinant Protein/Virus-Like Particle (VLP) Vaccines

The recombinant protein/virus-like particle (VLP) vaccines segment is expected to grow in the coming years, especially for RSV and influenza infections. Recombinant vaccines are made using bacterial or yeast cells through recombinant technology. Several studies have demonstrated the efficacy of recombinant F protein vaccines against severe RSV-related lower respiratory tract diseases.

Age Group/Indication Population Insights

How the Pediatrics Segment Dominated the Respiratory Disease Vaccine Market?

The pediatrics segment contributed the biggest revenue share of the market in 2024, due to favorable immunization programs for pediatrics and increasing awareness. Children receive vaccines against influenza, pneumococcal, pertussis, and measles to reduce acute respiratory infections. The Centers for Disease Control and Prevention (CDC) research found that routine vaccinations for children born during 1994-2023 will have prevented about 508 million illnesses, 32 million hospitalizations, and saved over 1.1 million lives.

Maternal Immunization

The maternal immunization segment is expected to expand rapidly in the respiratory disease vaccine market in the coming years. Maternal immunization is essential for pregnant women to prevent infection in the mother and fetus. It helps pregnant women to pass on disease-specific antibodies to the fetus during the second and early third trimesters. This protects the infant during the most vulnerable time of life.

Adults & Elderly

The adults & elderly segment is expected to show lucrative growth, due to the need for RSV, influenza, pneumonia, and COVID-19 immunization in the adult and elderly population. Adults are becoming more aware of the importance of vaccinations. The increasing travel to international countries also potentiates the need for travel vaccines. Favorable government initiatives propel the segment’s growth.

Route/Formulation Insights

What Made Intramuscular Injection the Dominant Segment in the Respiratory Disease Vaccine Market?

The intramuscular injection segment accounted for the highest revenue share of the market in 2024, due to high absorption and a strong immune response. Intramuscular injections are administered into the muscle through the skin and subcutaneous tissue. They are rapidly absorbed and have high bioavailability for precise dosage delivery. They have a reduced risk of adverse effects.

Intranasal/Mucosal

The intranasal/mucosal segment is expected to witness the fastest growth in the respiratory disease vaccine market over the forecast period. Intranasal administration of respiratory disease vaccines can prevent people from virus infection, replication, shedding, and disease development. Intranasal vaccines enhance patient convenience and accessibility, reducing injection site adverse effects. They can reduce the risk of injury and cross-contamination with pathogens.

Patch/Needle-Free

The patch/needle-free segment is expected to grow significantly, due to the growing need to reduce needlestick injuries and increasing awareness of targeted delivery of vaccines. Needle-free/patch vaccines enhance patients’ treatment compliance, reducing pain or swelling at the injection site. They also eliminate the need for skilled professionals to deliver vaccine dosages, facilitating self-administration.

End-User/Distribution Channel Insights

Which End-User/Distribution Channel Segment Led the Respiratory Disease Vaccine Market?

The public health programs/government immunization campaigns segment led the market in 2024, due to favorable government support and rising collaboration among intergovernmental organizations. Some programs and campaigns provide free vaccines to people, especially from low- and middle-income groups. They focus on universal immunization, reducing the economic burden of respiratory diseases on the healthcare sector.

Retail Pharmacies & Occupational/Workplace Vaccination

The retail pharmacies & occupational/workplace vaccination segment is expected to show the fastest growth over the forecast period. Retail pharmacies have a favorable infrastructure and suitable capital investment to store and manage vaccines. Workplace vaccination refers to offering accessible, convenient, and efficient immunization services to employees through partnerships with employers.

Hospitals & Clinics

The hospitals & clinics segment is expected to grow in the upcoming years. Hospitals & clinics have skilled professionals to guide patients about vaccination and administer vaccines. They are dominant for the high-risk and elderly population. Several government and private hospitals possess specific vaccines for different respiratory diseases.

Regional Analysis

Which Factors Govern the Respiratory Disease Vaccine Market in North America?

North America dominated the global market in 2024. The availability of state-of-the-art research and development facilities, a robust healthcare infrastructure, and the presence of key players are the factors that govern market growth in North America. Favorable government support and the increasing adoption of advanced technologies foster the market. Government and private bodies provide funding to favor the development and manufacturing of vaccines.

Alliance for Healthier America: Contributing to Market Dominance

The CDC reported that RSV is the leading cause of hospitalization in the U.S. Hence, appropriate measures are taken to improve vaccination among the elderly. The Infectious Diseases Society of America (IDSA) developed rapid guidelines for the use of U.S.-licensed vaccines against COVID-19, influenza, and RSV in adult and pediatric patients to support evidence-based clinical & shared decision-making during the 2025-2026 respiratory tract infection season.

What Makes Asia-Pacific the Fastest-Growing Region in the Respiratory Disease Vaccine Market?

Asia-Pacific is expected to grow at the fastest CAGR in the market during the forecast period. Government organizations raise awareness about disease prevention and vaccination among the general population. The increasing prevalence of respiratory diseases and the growing pediatric and geriatric populations augment the market. The rising collaboration among key players and public-private partnerships propels market growth. The MCRI’s Asia-Pacific Vaccine Research Network supports vaccine research and policy in LMICs to boost immunization equity.

India’s Biotech Boom Promotes Market Growth

India has a suitable manufacturing infrastructure, encouraging foreign companies to set up their manufacturing facilities in the nation. The burgeoning biotech sector and the increasing number of biotech startups also contribute to market growth. As of February 2025, there are over 9,000 biotech startups in India. Bharat Biotech and Serum Institute of India are major local vaccine manufacturers in India.

Will Europe Grow in the Respiratory Disease Vaccine Market?

Europe is considered to be a significantly growing area, due to favorable regulatory support, established adult and pediatric programs, and strong procurement budgets. The European Medicines Agency (EMA) regulates the approval of vaccines in Europe. The region has a strong presence of biotech companies, facilitating vaccine manufacturing. Most European HCPs view vaccination against respiratory disease to be an essential tool for self-protection and patient care.

Major Players Fuel UK’s Vaccine Development

Key players, such as GlaxoSmithKline and AstraZeneca, are UK-based companies that are the major contributors to the market globally. The UK government formed the Moderna Innovation and Technology Centre, in collaboration with Moderna, to invest £1 billion in UK R&D. This investment will support Moderna to make millions of vaccines for seasonal viruses like COVID-19 and help build a Britain that’s more resilient to pandemics.

South America’s Immunization Revival

The respiratory disease vaccine market in South America is expanding due to rising influenza and pneumonia cases. Governments are prioritizing vaccination campaigns, with improved distribution networks and awareness programs ensuring wider access, especially in rural areas affected by respiratory infections.

Brazil’s Preventive Push Gains Momentum

Brazil’s respiratory disease vaccine market thrives on government-backed immunization drives and strong public healthcare infrastructure. Increasing adult vaccination coverage and high incidence of influenza and RSV cases are accelerating demand for advanced vaccines, strengthening Brazil’s leadership in respiratory vaccine adoption and distribution nationwide.

MEA’s Expanding Health Infrastructure

The Middle East and Africa are witnessing significant growth in respiratory disease vaccination, supported by increasing investments in healthcare systems and disease awareness programs. With respiratory infections among the leading regional health burdens, immunization strategies are focusing on both preventive coverage and vaccine innovation.

GCC’s Health Vision Driving Vaccination

The GCC respiratory disease vaccine market is growing rapidly, supported by strong government initiatives, modern healthcare policies, and public awareness. High prevalence of influenza and pneumonia cases drives large-scale vaccination programs, reinforcing the region’s commitment to respiratory health advancement.

Value Chain Analysis - Respiratory Disease Vaccine Market

R&D

The latest research activities involve developing novel vaccines to deal with viral variants and developing novel drug delivery systems for vaccines.

Key Players: AstraZeneca, Pfizer, and Dr. Reddy’s Laboratories.

Clinical Trials & Regulatory Approval

Clinical trials are conducted to assess the safety and efficacy of vaccines and study their immune responses in preventing respiratory diseases.

Key Players: GlaxoSmithKline, Medicago, Inc., and Janssen Vaccines & Prevention B.V.

Distribution to Hospitals, Pharmacies

Vaccines are delivered to hospitals and retail pharmacies, either directly through manufacturers or through wholesalers or distributors.

Key Players: FFF Enterprises, Inc., Aark Pharmaceuticals

Patient Support & Services

Patient support & services refer to the focus on education, accessibility, and financial assistance to patients.

Company Landscape

Pfizer Inc.

Company Overview:

• A leading American multinational pharmaceutical and biotechnology corporation.
• Focuses on the discovery, development, manufacture, and commercialization of healthcare products, including medicines and vaccines, for humans.
• The company is globally recognized for its contribution to the COVID-19 vaccine response.

Corporate Information:

• Headquarters: New York City, New York, USA
• Year Founded: 1849
• Ownership Type: Public (NYSE: PFE)

History and Background:

• Founded by two German cousins, Charles Pfizer and Charles F. Erhart, as a chemical company.
• Initially produced fine chemicals, famously providing mass quantities of penicillin during World War II.
• Transformed into a research-driven pharmaceutical company over the 20th century through organic growth and major acquisitions.

Key Milestones/Timeline:

• 1849: Founded as Charles Pfizer & Company.
• 1950s: Expanded globally, establishing offices across the world.
• 2000s: Major acquisitions include Warner-Lambert, Pharmacia, and Wyeth.
• 2020: Joint development with BioNTech of the first mRNA-based COVID-19 vaccine authorized for emergency use in the US and EU.
• 2023: US FDA approval for ABRYSVO™ (RSV vaccine) for older adults and for pregnant individuals to prevent RSV in infants.

Business Overview:

• Operates across a wide range of therapeutic areas, including Vaccines, Oncology, Inflammation & Immunology, Rare Diseases, Internal Medicine, and Sterile Injectable Pharmaceuticals.
• The Vaccines segment is a key growth driver, heavily weighted toward pneumococcal and COVID-19/RSV vaccines.

Business Segments/Divisions:

Pfizer Biopharmaceuticals Group (Biopharma): Divided into six therapeutic areas/categories: Internal Medicine, Inflammation & Immunology, Oncology, Rare Disease, Hospital (Sterile Injectable Pharmaceuticals and Anti-Infectives), and Vaccines.

Geographic Presence:

• Sells products in more than 180 countries and territories globally.
• Major revenue sources include North America and Europe, with a growing presence in emerging markets.

Key Offerings (Respiratory Vaccines):

• Comirnaty (in partnership with BioNTech): mRNA COVID-19 vaccine.
• Prevnar Family (e.g., Prevnar 13, Prevnar 20/Vaxneuvance): Pneumococcal Conjugate Vaccines (PCV) for infants, children, and adults.
• ABRYSVO™: Respiratory Syncytial Virus (RSV) vaccine for older adults and maternal immunization.

End-Use Industries Served:

• Hospitals and Clinics
• Retail and Hospital Pharmacies
• Government Agencies/Public Health Programs
• Pediatric and Adult Patient Populations

Key Developments and Strategic Initiatives:

• Mergers & Acquisitions:

2022: Completed the acquisition of ReViral, a clinical-stage biopharmaceutical company focused on antiviral therapeutics for Respiratory Syncytial Virus (RSV).

• Partnerships & Collaborations:

Continues its collaboration with BioNTech for the development and commercialization of mRNA-based vaccines, including updated COVID-19 and combination vaccine candidates.

• Product Launches/Innovations:

Development of next-generation mRNA technology platforms to target multiple respiratory pathogens simultaneously (e.g., flu/COVID-19 combination vaccine candidates).

• Capacity Expansions/Investments:

Continues to invest heavily in its manufacturing network to support the global supply of its pneumococcal, COVID-19, and RSV vaccines.

• Regulatory Approvals:

April 2025: Announced the amendment in the marketing authorization for ABRYSVO (RSV vaccine) to include the extension of indication for the prevention of Lower Respiratory Tract Disease (LRTD) caused by RSV in new populations.

• Distribution Channel Strategy:

Multi-channel approach: Utilizes Hospital Pharmacies and Retail Pharmacies for adult and pediatric vaccinations, and Government Suppliers for national immunization programs globally.

• Technological Capabilities/R&D Focus:
  • Core Technologies/Patents: mRNA technology, Conjugate Vaccine technology (for pneumococcal), and Prefusion F protein technology (for RSV).
  • Research & Development Infrastructure: Global R&D centers in the US, Europe, and Asia. Focus on highly innovative, breakthrough therapies and vaccines.
  • Innovation Focus Areas: Combination respiratory vaccines (e.g., Flu/COVID-19), next-generation pneumococcal vaccines, and expanded indications for RSV prevention.

Competitive Positioning:

• Strengths & Differentiators:
  • Market leadership in the high-value Pneumococcal and COVID-19 vaccine segments.
  • Early mover advantage in the new RSV adult and maternal vaccine market.
  • Robust and flexible mRNA platform technology for rapid response to new pathogens.
  • Market presence & ecosystem role: Global pharmaceutical powerhouse with established relationships with governments and healthcare providers worldwide, acting as a critical supplier for pandemic-response and routine immunization.
• SWOT Analysis:
  • Strengths: Strong brand recognition; leading position in PCV, COVID-19, and new RSV markets; diversified pipeline; extensive global manufacturing and distribution.
  • Weaknesses: High dependence on a few blockbuster products; recent revenue fluctuations post-COVID-19 vaccine peak.
  • Opportunities: Expansion of RSV vaccine into new demographics; development of combination respiratory vaccines (e.g., Flu/COVID-19); geographic expansion in emerging markets.
  • Threats: Patent expiry for key drugs; intense competition in the vaccine landscape (especially from GSK and Moderna); regulatory scrutiny.

Recent News and Updates:

Press Releases:

• August 2024: Reported positive top-line results from a Phase 3 trial evaluating the mRNA vaccine candidate against influenza and COVID-19.
• April 2025: Received an extended indication approval for ABRYSVO for certain populations.

Industry Recognitions/Awards:

Consistently recognized for leadership in vaccine development and manufacturing innovation.

GlaxoSmithKline (GSK) plc

Company Overview:

• A British multinational pharmaceutical and biotechnology company.
• One of the largest vaccine manufacturers globally, with a dedicated focus on the prevention and treatment of infectious and respiratory diseases.
• GSK's Vaccines division is a core part of its biopharma strategy.

Corporate Information:

• Headquarters: Brentford, London, United Kingdom
• Year Founded: 2000 (Formed by the merger of Glaxo Wellcome and SmithKline Beecham, tracing origins back to the 18th century)
• Ownership Type: Public (LSE: GSK, NYSE: GSK)

History and Background:

• A long history in the pharmaceutical industry through its predecessor companies.
• The merger in 2000 created one of the world's largest pharmaceutical companies.
• Has focused heavily on building a dominant Vaccines portfolio, which has become a key driver of the company's growth.

Key Milestones/Timeline:

• 2000: Formation of GSK through merger.
• 2015: Acquired Novartis’s vaccine business (excluding influenza).
• 2017: Launched Shingrix (non-respiratory, but a major vaccine success).
• 2022: Spun off its Consumer Healthcare division (Haleon) to focus purely on biopharma and vaccines.
• 2023: US FDA approval for Arexvy (RSV vaccine) for adults 60 years and older.

Business Overview:

• Focused biopharma company with R&D in four core therapeutic areas: Infectious Diseases, HIV, Oncology, and Immunology/Respiratory.
• Vaccines are managed under the Infectious Diseases and Respiratory/Immunology focus areas, contributing significantly to group revenue.

Business Segments/Divisions:

• Pharmaceuticals: Focuses on respiratory, HIV, oncology, and specialty medicines.
• Vaccines: Develops, manufactures, and distributes vaccines to prevent a wide range of infectious diseases, including major respiratory pathogens.

Geographic Presence:

• Operates in over 100 countries, with vaccines distributed to more than 170 countries.
• Significant presence in North America, Europe, and a long-standing commitment to lower-income countries through global health initiatives.

Key Offerings (Respiratory Vaccines):

• Arexvy: Respiratory Syncytial Virus (RSV) vaccine for adults 60 years and older.
• Fluarix/FluLaval/FluMist: Portfolio of Influenza vaccines (Quadrivalent/Nasal Spray).
• Bexsero: Meningococcal Group B vaccine (a major respiratory-linked disease).
• Synflorix: Pneumococcal Conjugate Vaccine (PCV) for infants and children (competes with Pfizer's Prevnar).

End-Use Industries Served:

• Public Health Systems and Government Immunization Programs (especially for pediatric and seasonal vaccines) 
• Hospitals and Clinics
• Retail Pharmacies and Private Healthcare Providers

Key Developments and Strategic Initiatives:

• Mergers & Acquisitions:

2022: Acquired Affinivax Inc. to enhance its pneumococcal vaccine pipeline, including a next-generation 24-valent pneumococcal vaccine candidate (AFX3772).

• Partnerships & Collaborations:

June 2023: Announced funding agreement with the Bill & Melinda Gates Foundation and Wellcome to accelerate late-stage development of its tuberculosis vaccine candidate, M72 (TB is a major chronic respiratory disease).

• Product Launches/Innovations:
  • Successful launch of Arexvy in the adult RSV market in 2023, a significant respiratory disease vaccine innovation.
  • Focusing on developing next-generation pneumococcal and meningococcal vaccines.

Capacity Expansions/Investments:

Continuously investing in its global manufacturing network to meet high demand for its new and established vaccine products.

Regulatory Approvals:

April 2025: Announced that the CDC's Advisory Committee on Immunization Practices (ACIP) voted to endorse the inclusion of Penmenvy (Meningococcal Groups A, B, C, W, and Y Vaccine) in the adolescent meningococcal vaccination schedule.

Distribution Channel Strategy:

• Leverages strong government relationships for national and global immunization programs.
• Extensive network with hospitals and retail pharmacies for widespread administration of seasonal and adult vaccines (e.g., flu, RSV).

Technological Capabilities/R&D Focus:

• Core Technologies/Patents: Adjuvants (e.g., AS01E used in Arexvy and Shingrix), Conjugate Vaccine technology, and Recombinant protein technology.
• Research & Development Infrastructure: Focused R&D centers globally, with a strong emphasis on Infectious Diseases and the use of genetic data.
• Innovation Focus Areas: Next-generation bacterial vaccines (e.g., pneumococcal), RSV prevention, and new vaccine platforms for infectious diseases.

Competitive Positioning:

• Strengths & Differentiators:
  • World-class adjuvant technology (AS01E) demonstrated in Shingrix and Arexvy.
  • Diversified vaccine portfolio spanning pediatric to adult immunization.
  • Deep expertise and long-standing presence in the respiratory and infectious disease areas.
  • Market presence & ecosystem role: A core provider to global health organizations (like Gavi) and a dominant player in the global adult and pediatric vaccine market.
• SWOT Analysis:
  • Strengths: Leading global vaccine manufacturer; strong late-stage pipeline (PCV, TB); successful entry into the high-value RSV market; robust adjuvant platform.
  • Weaknesses: Lagging in the COVID-19 mRNA vaccine space compared to Pfizer/Moderna; historical legal and regulatory challenges.
  • Opportunities: Maximizing the growth potential of Arexvy in the RSV market; advancing next-generation pneumococcal vaccines (e.g., AFX3772); expanding global access programs.
  • Threats: Intense competition in the RSV market from Pfizer and Moderna; pricing pressure in government tenders; manufacturing complexity of its broad portfolio.

Recent News and Updates:

• Press Releases:
• • October 2023: Signed a partnership deal with Zhi Fei Biological to co-promote Shingrix (shingles vaccine) in China, leveraging its distribution for other vaccines.
  • April 2025: CDC ACIP endorsement for its MenACYW vaccine, Penmenvy, strengthening its meningococcal portfolio.

Industry Recognitions/Awards:

Frequently recognized for contributions to global immunization and public health, particularly for its innovative adjuvant system.

Top Companies & Their Offerings in the Respiratory Disease Vaccine Market

Other Companies

• Sanofi Pasteur
• Seqirus (CSL Group)
• Bharat Biotech
• Serum Institute of India
• Novavax
• Valneva
• Sinovac Biotech
• Sinopharm
• Bavarian Nordic
• Medicago, Inc.
• SK Bioscience
• Anhui Zhifei Longcom

Recent Developments in the Respiratory Disease Vaccine Market

• In July 2025, Emory University and Micron Biomedical announced the initiation of their first clinical trial for a novel rotavirus vaccine, CC24. The trial evaluates the safety and effectiveness of a vaccine administered using dissolvable microarray technology. CC24 aims to save the lives of children from rotavirus illness and death.
• In May 2025, Yale researchers found that nasal vaccine boosters can trigger strong immune defenses in the respiratory tract even without the help of adjuvants. These findings may offer critical insights into developing safer, more effective nasal vaccines in the future.

Segments Covered in the Report

By Target Disease/Indication

• Influenza Vaccines
• Respiratory Syncytial Virus (RSV) Vaccines
• Pneumococcal Vaccines (PCV & PPSV)
• COVID-19 Vaccines
• Pertussis
• Other Respiratory Targets

By Vaccine Technology/Platform

• Inactivated/Split & Subunit Vaccines
• mRNA Vaccines
• Conjugate Vaccines
• Recombinant Protein/Virus-like Particle (VLP) Vaccines
• Live Attenuated Vaccines
• Viral Vector & Other Novel Platforms

By Age Group/Indication Population

• Pediatrics
• Maternal Immunization
• Adults & Elderly
• High-Risk/Comorbidity Groups

By Route/Formulation

• Intramuscular Injection
• Intranasal/Mucosal
• Oral
• Patch/Needle-free

By End-User

• Public Health Programs/Government Immunization Campaigns
• Retail Pharmacies & Occupational/Workplace Vaccination
• Hospitals & Clinics
• Private Providers/Travel Clinics
• Long-term Care Facilities & Nursing Homes

By Region

• North America
  • US
  • Canada
  • Mexico
  • Rest of North America
• South America
  • Brazil
  • Argentina
  • Rest of South America
• Europe
  • Western Europe
    • Germany
    • Italy
    • France
    • Netherlands
    • Spain
    • Portugal
    • Belgium
    • Ireland
    • UK
    • Iceland
    • Switzerland
    • Poland
    • Rest of Western Europe
• Eastern Europe
  • Austria
  • Russia & Belarus
  • Turkiye
  • Albania
  • Rest of Eastern Europe
• Asia Pacific (APAC)
  • China
  • Taiwan
  • India
  • Japan
  • Australia & New Zealand
  • ASEAN Countries (Singapore, Malaysia)
  • South Korea
  • Rest of APAC
• Middle East and Africa (MEA)
  • GCC Countries
  • Saudi Arabia
  • United Arab Emirates (UAE)
  • Qatar
  • Kuwait
  • Oman
  • Bahrain
• South Africa
• Egypt
• Rest of MEA